Back to Search Start Over

1438TiP INTEGRATE IIb: A randomised phase III open label study of regorafenib + nivolumab vs standard chemotherapy in refractory advanced gastro-oesophageal cancer (AGOC).

Authors :
Pavlakis, N.
Shitara, K.
Sjoquist, K.
Martin, A.J.
Jaworski, A.
Yip, S.
Oh, D-Y.
Moehler, M.
Chen, L-T.
Bekaii-Saab, T.
Simes, J.
Goldstein, D.
Source :
Annals of Oncology. 2021 Supplement 5, Vol. 32, pS1074-S1074. 1p.
Publication Year :
2021

Subjects

Subjects :
*NIVOLUMAB
*REGORAFENIB
*CANCER chemotherapy
*STANDARDS

Details

Language :
English
ISSN :
09237534
Volume :
32
Database :
Academic Search Index
Journal :
Annals of Oncology
Publication Type :
Academic Journal
Accession number :
152689632
Full Text :
https://doi.org/10.1016/j.annonc.2021.08.1547
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details